高级检索
当前位置: 首页 > 详情页

Clinical effectiveness of pemetrexed combined with cisplatin chemotherapy for advanced and maintenance treatment for patients with non-small-cell lung cancer

| 认领 | 导出 |

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

单位: [1]Department of Respiration Medicine, The Sixth People’s Hospital of Chongqing, Chongqing, China [2]Department of Pulmonary & Critical Care Medicine, China-Japan Friendship Hospital, Beijing, China
出处:
ISSN:

关键词: Pemetrexed Cisplatin Non-small-cell lung cancer Progressive stage

摘要:
OBJECTIVE: To evaluate the clinical effectiveness of pemetrexed combined with cisplatin for the first-line chemotherapy of patients with advanced non-small-cell lung cancer (NSCLC) and maintenance treatment. PATIENTS AND METHODS: 240 advanced NSCLC patients were randomly divided into either a control group (treated with gemcitabine combined with cisplatin) or an observation group (treated with pemetrexed combined with cisplatin). The primary treatment was defined as first-line chemotherapy, and the maintenance treatment was defined as retreatment. The demographic data from both groups were statistically similar. Patients were treated for 21 days for each cycle and underwent between 4 to 6 treatment cycles. RESULTS: The mid-and-long term efficacy between groups was compared using efficacy indexes [ objective response rate (ORR), disease control rate (DCR), and chemotherapy toxic reaction rate] and progression-free survival (PFS), median survival time, and one-year survival rates. The observation group showed a statically greater (p<0.05) ORR and DCR than the control group. Comparison of the prevalence of toxic reaction above level III between the two groups revealed no statistical difference (p>0.05). The PFS, median survival time, and one-year survival rate of the observation group were statistically longer (p<0.05) than those of the control group. CONCLUSIONS: Pemetrexed combined with cisplatin was both safe and efficacious for the first-line chemotherapy of NSCLC patients at a progressive stage and for maintenance treatment.

语种:
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 4 区 医学
小类 | 4 区 药学
最新[2025]版:
JCR分区:
出版当年[2016]版:
Q3 PHARMACOLOGY & PHARMACY
最新[2023]版:

影响因子: 最新[2023版] 最新五年平均[2021-2025] 出版当年[2016版] 出版当年五年平均[2012-2016] 出版前一年[2015版] 出版后一年[2017版]

第一作者:
第一作者单位: [1]Department of Respiration Medicine, The Sixth People’s Hospital of Chongqing, Chongqing, China [2]Department of Pulmonary & Critical Care Medicine, China-Japan Friendship Hospital, Beijing, China
通讯作者:
通讯机构: [1]Department of Respiration Medicine, The Sixth People’s Hospital of Chongqing, Chongqing, China [2]Department of Pulmonary & Critical Care Medicine, China-Japan Friendship Hospital, Beijing, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:1320 今日访问量:0 总访问量:817 更新日期:2025-06-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)